Imago Bio Shares Soar on Agreement to Selll to Merck for $1.35 Billion Cash
Wednesday, 23 November 2022, 22:09:42
Pharmaceutical giant Merck has offered to acquire biopharma firm Imago Biosciences for $1.35 billion.
— 24/7 Wall street
Wednesday, 23 November 2022, 16:15:53
While billionaire Elon Musk has reinstated the Twitter accounts of insurrectionists and transphobes like Donald Trump and Rep. Marjorie Taylor Greene (R-Ga.), half of Twitter’s top 100 advertisers have pulled ads on the microblogging platform over the last two weeks, according to The Washington Post and Media Matters . Analyzing data from Pathmatics, a digital marketing trend research company, the publication found that vehicle maker Jeep; food makers Mars, Coca-Cola, Kraft Heinz, Nestle, and Kellogg; telecommunications corporations AT&T and Verizon; fashion brand Chanel; hoteliers Hilton and Marriott; auto manufacturers Chevrolet and Ford; pharmaceutical giant Merck; and beer brewer Samuel Adams have all stopped advertising on the site since Musk took it over. “Mars started suspending advertising activities on Twitter in late September when we learned of some significant brand safety and suitability incidents that impacted our brand,” the company wrote to the Post . The other companies didn’t submit statements.
— AlterNet
Merck PT Raised to $115 at Berenberg
Wednesday, 23 November 2022, 13:37:01
https://www.investing.com/news/pro/merck-pt-raised-to-115-at-berenberg-432SI-2950777
— Investing.com
Latham & Watkins Advises Imago BioSciences in Acquisition by Merck for US$1.35 Billion
Wednesday, 23 November 2022, 08:01:07
Merck (NYSE: MRK) and Imago BioSciences, Inc. (Nasdaq: IMGO) have announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for US$36 per share in cash for an approximate total equity value of US$1.35 billion. The transaction is expected to close in the first quarter of […] The post Latham & Watkins Advises Imago BioSciences in Acquisition by Merck for US$1.35 Billion appeared first on Legal Desire .
— Legal Desire
10-Year Phase 3 Trial Shows CEL-SCI”s Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients
Tuesday, 22 November 2022, 18:21:37
CEL-SCI Corporation (NYSE: CVM ) said that its 10-year Phase 3 trial showed that Multikine immunotherapy significantly extended the lives of patients with locally advanced primary squamous cell carcinoma of the head and neck (SCCHN). The company says that current drug therapies for SCCHN from Merck & Co Inc (NYSE: MRK ) and Bristol Myers Squibb & Co (NYSE: BMS ) are approved as a last resort. The Multikine treated study … Full story available on Benzinga.com
— Benzinga
We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.
